Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2017-06-26

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1073/pnas.1706139114PMID 28652330PMCID PMC5514758
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tuberculosis drug discovery needs public-private consortia.

  2017cited by this paper
• WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea

  2017cited by this paper
• The number of privately treated tuberculosis cases in India: an estimation from drug sales data

  2016cited by this paper
• Lansoprazole is an antituberculous prodrug targeting cytochrome bc1

  2015cited by this paper
• Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

  2015cited by this paper
• Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

  2015cited by this paper
• Specialized Transduction Designed for Precise High-Throughput Unmarked Deletions in Mycobacterium tuberculosis

  2014cited by this paper
• A Mycobacterium tuberculosis Cytochrome bd Oxidase Mutant Is Hypersensitive to Bedaquiline

  2014cited by this paper
• Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.

  2014cited by this paper
• Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

  2014cited by this paper
• Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria

  2014cited by this paper
• Energetics of pathogenic bacteria and opportunities for drug development.

  2014cited by this paper
• Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis

  2014cited by this paper
• Mapping of Genotype–Phenotype Diversity among Clinical Isolates of Mycobacterium tuberculosis by Sequence-Based Transcriptional Profiling

  2013cited by this paper
• Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

  2013cited by this paper
• Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB

  2012cited by this paper
• University of Birmingham Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB

  2012cited by this paper
• Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.

  2011cited by this paper
• A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

  2010cited by this paper
• The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

  2009cited by this paper
• Synthesis of DNA fragments in yeast by one-step assembly of overlapping oligonucleotides

  2009cited by this paper
• Biogenesis of the yeast cytochrome bc1 complex.

  2009cited by this paper
• Physiology of mycobacteria.

  2009cited by this paper
• The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

  2008cited by this paper
• Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis*

  2008cited by this paper
• Multi-target therapeutics: when the whole is greater than the sum of the parts.

  2007cited by this paper
• A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

  2005cited by this paper
• Function of the Cytochrome bc1-aa3 Branch of the Respiratory Network in Mycobacteria and Network Adaptation Occurring in Response to Its Disruption

  2005cited by this paper
• Genes required for mycobacterial growth defined by high density mutagenesis

  2003cited by this paper
• Protonmotive pathways and mechanisms in the cytochrome bc 1 complex

  2003cited by this paper
• Redundancy of aerobic respiratory chains in bacteria? Routes, reasons and regulation.

  2000cited by this paper
• Enhanced gene replacement in mycobacteria.

  1999cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• New use of BCG for recombinant vaccines

  1991cited by this paper
• The physiology of the mycobacteria.

  1976cited by this paper
• Supplementary Information Supplementary Figures

  year unknowncited by this paper

• A bactericidal tuberculosis drug regimen driven by inhibition of the terminal oxidases by pretomanid.

  2026cites this paper
• A Series of Pyrazolo-Quinazoline Amines Inhibits the Cytochrome bd Oxidase in Mycobacterium tuberculosis.

  2026cites this paper
• Mycobacterial respiratory chain enzymes and growth are inhibited by decylubiquinone

  2025cites this paper
• Essential redundancies fuel Mycobacterium tuberculosis adaptation to the host

  2025cites this paper
• Targeting Metabolic Vulnerabilities: Valinomycin Augments the Potency of Bioenergetic Inhibitors in Combatting Drug-Resistant and Dormant Mycobacterium tuberculosis

  2025cites this paper
• Cytochrome bd-II oxidase CyxA promotes the pathogenicity of Klebsiella pneumoniae by resisting oxidative stress

  2025cites this paper
• A bioluminescence-based chemical screen identifies a bactericidal naphthalene scaffold targeting MmpL3 in Mycobacterium abscessus

  2025cites this paper
• Inhibition of cytochrome bd oxidase in Mycobacterium tuberculosis by benzothiazole amides.

  2025cites this paper
• Targeting drug-resistant tuberculosis: Thioacetamide-substituted benzothiazoles as bactericidal agents inhibiting type II NADH dehydrogenase.

  2025cites this paper
• Chalkophore-mediated respiratory oxidase flexibility controls M. tuberculosis virulence

  2025influential citation
• Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype.

  2025cites this paper
• Unprecedented in vivo activity of telacebec against Mycobacterium leprae

  2025cites this paper
• Chemical Synthetic Lethality Screens Identify Selective Drug Combinations against Pseudomonas aeruginosa.

  2025cites this paper
• Whole-Cell Study Unveils Critical Mechanistic Elements, Regulatory Elements, and Inhibitor Targets of the Mycobacterium abscessus Cytochrome bd Oxidase.

  2025cites this paper
• Structural and mechanistic study of a novel inhibitor analogue of M. tuberculosis cytochrome bc1:aa3

  2025cites this paper
• Drug-loaded liposomes for macrophage targeting in Mycobacterium tuberculosis: development, characterization and macrophage infection study

  2025cites this paper
• Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target.

  2025cites this paper
• A cytochrome bd repressed by a MarR family regulator confers resistance to metals, nitric oxide, sulfide, and cyanide in Chromobacterium violaceum

  2025cites this paper
• Divergent transcriptional regulation of redox-homeostasis and permeability modulate rifampicin tolerance and sensitivity in Mycobacterium tuberculosis

  2025cites this paper
• Design, Synthesis, Evaluation of Antitubercular Activity and Insilco Studies of Novel 1,5‐Naphthyridin‐2(1H)‐One Pendent 1,2,3‐Triazoles

  2024cites this paper
• Menaquinone-specific turnover by Mycobacterium tuberculosis cytochrome bd is redox regulated by the Q-loop disulfide bond

  2024cites this paper
• Interplay of niche and respiratory network in shaping bacterial colonization

  2024cites this paper
• Mycobacterium tuberculosis F-ATP Synthase Inhibitors and Targets

  2024cites this paper
• Inhibition mechanism of potential antituberculosis compound lansoprazole sulfide

  2024cites this paper
• The progress of Mycobacterium tuberculosis drug targets

  2024cites this paper
• 2-Aryl-Benzoimidazoles as Type II NADH Dehydrogenase Inhibitors of Mycobacterium tuberculosis.

  2024cites this paper
• Respiration suppress and apoptosis-like cell death of Escherichia coli in direct current therapy mediated by polypyrrole conductive hydrogel.

  2024cites this paper
• A Review of Antibacterial Candidates with New Modes of Action

  2024cites this paper
• Contribution of telacebec to novel drug regimens in a murine tuberculosis model

  2024cites this paper
• Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting Mycobacterium tuberculosis type II NADH dehydrogenase.

  2024cites this paper
• Chalkophore mediated respiratory oxidase flexibility controls M. tuberculosis virulence

  2024cites this paper
• Targeting Tuberculosis: Novel Scaffolds for Inhibiting Cytochrome bd Oxidase

  2024cites this paper
• In silico drug design strategies for discovering novel tuberculosis therapeutics

  2024cites this paper
• Identification of genes associated with persistence in Mycobacterium smegmatis

  2024cites this paper
• Cytochrome bd oxidase: an emerging anti-tubercular drug target.

  2024cites this paper
• Metabolic Rewiring of Mycobacterium tuberculosis upon Drug Treatment and Antibiotics Resistance

  2024cites this paper
• Menaquinone-specific oxidation by M. tuberculosis cytochrome bd is redox regulated by the Q-loop disulfide bond

  2024cites this paper
• Exploring ND-011992, a quinazoline-type inhibitor targeting quinone reductases and quinol oxidases

  2023cites this paper
• 3-Methoxy-2-phenylimidazo[1,2-b]pyridazines highly active against Mycobacterium tuberculosis and Mycobacterium marinum.

  2023cites this paper
• Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc1 Complex

  2023cites this paper
• Novel targets and inhibitors of the Mycobacterium tuberculosis cytochrome bd oxidase to foster anti-tuberculosis drug discovery

  2023cites this paper
• Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli.

  2023cites this paper
• Mycobacterial Genetic Technologies for Probing the Host-Pathogen Microenvironment

  2023cites this paper
• Inhibiting respiration as a novel antibiotic strategy.

  2023cites this paper
• Cryo-Electron Microscopy Structure of the Mycobacterium tuberculosis Cytochrome bcc:aa3 Supercomplex and a Novel Inhibitor Targeting Subunit Cytochrome cI

  2023cites this paper
• Molecular diagnostics and potential therapeutic options for Mycobacterium tuberculosis: Where we stand

  2023cites this paper
• M. tuberculosis relies on trace oxygen to maintain energy homeostasis and survive in hypoxic environments.

  2023cites this paper
• Synthetic lethality of Mycobacterium tuberculosis NADH dehydrogenases is due to impaired NADH oxidation

  2023cites this paper
• An insight on the prospect of quinazoline and quinazolinone derivatives as anti-tubercular agents.

  2023cites this paper
• Mutating the environment of heme b595 of E. coli cytochrome bd-I oxidase shifts its redox potential by 200 mV without inactivating the enzyme.

  2023cites this paper
• Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome bd and Chemical Validation of Combination Strategies for Respiratory Inhibitors against Mycobacterium tuberculosis

  2023cites this paper
• A dual-targeting succinate dehydrogenase and F1Fo-ATP synthase inhibitor rapidly sterilizes replicating and non-replicating Mycobacterium tuberculosis.

  2023cites this paper
• Telacebec Interferes with Virulence Lipid Biosynthesis Protein Expression and Sensitizes to Other Antibiotics

  2023cites this paper
• An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis

  2022cites this paper
• Sensitivity of Mycobacterium leprae to Telacebec

  2022cites this paper
• Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase—a molecular modelling perspective

  2022cites this paper
• Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB)

  2022cites this paper
• pH-dependent kinetics of NO release from E. coli bd-I and bd-II oxidase reveals involvement of Asp/Glu58B.

  2022cites this paper
• Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis

  2022cites this paper
• Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis

  2022cites this paper
• Mycobacterium tuberculosis functional genetic diversity, altered drug sensitivity, and precision medicine

  2022cites this paper
• Synthesis and Biological Evaluation of Aurachin D Analogues as Inhibitors of Mycobacterium tuberculosis Cytochrome bd Oxidase.

  2022cites this paper
• Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy.

  2022cites this paper
• Response of Mycobacterium smegmatis to the Cytochrome bcc Inhibitor Q203

  2022cites this paper
• Uncovering interactions between mycobacterial respiratory complexes to target drug-resistant Mycobacterium tuberculosis

  2022influential citation
• Determination of Bioenergetic Parameters in Mycobacterium ulcerans.

  2022cites this paper
• Design, synthesis and biological evaluation of (Quinazoline 4-yloxy)acetamide and (4-oxoquinazoline-3(4H)-yl)acetamide derivatives as inhibitors of Mycobacterium tuberculosis bd oxidase.

  2022cites this paper
• Bioenergetics and Reactive Nitrogen Species in Bacteria

  2022cites this paper
• The Orphan Response Regulator Rv3143 Modulates the Activity of the NADH Dehydrogenase Complex (Nuo) in Mycobacterium tuberculosis via Protein–Protein Interactions

  2022cites this paper
• Computational methods, databases and tools for synthetic lethality prediction

  2022cites this paper
• On the Hunt for Next-Generation Antimicrobial Agents: An Online Symposium Organized Jointly by the French Society for Medicinal Chemistry (Société de Chimie Thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) on 9–10 December 2021

  2022cites this paper
• Recent Advances in Structural Studies of Cytochrome bd and Its Potential Application as a Drug Target

  2022cites this paper
• Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine, and Linezolid in a Murine Model of Tuberculosis

  2021cites this paper
• QcrB in Mycobacterium tuberculosis: The new drug target of antitubercular agents

  2021cites this paper
• Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis

  2021cites this paper
• Identification and optimization of quinolone-based inhibitors against cytochrome bd oxidase using an electrochemical assay

  2021cites this paper
• Electrocatalytic evidence of the diversity of the oxygen reaction in the bacterial bd oxidase from different organisms.

  2021cites this paper
• Structure guided generation of thieno[3,2-d]pyrimidin-4-amine Mycobacterium tuberculosis bd oxidase inhibitors.

  2021cites this paper
• Hydride-induced Meisenheimer complex formation reflects activity of nitro aromatic anti-tuberculosis compounds.

  2021cites this paper
• Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis

  2021cites this paper
• Impaired Succinate Oxidation Prevents Growth and Influences Drug Susceptibility in Mycobacterium tuberculosis

  2021cites this paper
• The future of antibiotics begins with discovering new combinations

  2021cites this paper
• Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis

  2021influential citation
• Structure of mycobacterial CIII2CIV2 respiratory supercomplex bound to the tuberculosis drug candidate telacebec (Q203)

  2021cites this paper
• Cryo-EM structure of mycobacterial cytochrome bd reveals two oxygen access channels

  2021cites this paper
• The cryo-EM structure of the bd oxidase from M. tuberculosis reveals a unique structural framework and enables rational drug design to combat TB

  2021cites this paper
• Opportunities for overcoming tuberculosis: emerging targets and their inhibitors.

  2021cites this paper
• The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus

  2021cites this paper
• Multiplexed transcriptional repression identifies a network of bactericidal interactions between mycobacterial respiratory complexes

  2021cites this paper
• Study of the bioenergetics to identify the novel pathways as a drug target against Mycobacterium tuberculosis using Petri net

  2021cites this paper
• Targeting the cytochrome bc1 complex for drug development in M. tuberculosis: review

  2021cites this paper
• Syntheses and Structure–Activity Relationships of N-Phenethyl-Quinazolin-4-yl-Amines as Potent Inhibitors of Cytochrome bd Oxidase in Mycobacterium tuberculosis

  2021cites this paper
• Mechanistic and structural diversity between cytochrome bd isoforms of Escherichia coli

  2021cites this paper
• Targeting the menaquinol binding loop of mycobacterial cytochrome bd oxidase

  2020cites this paper
• Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds

  2020cites this paper
• Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?

  2020cites this paper
• Microbial energy management-A product of three broad tradeoffs.

  2020cites this paper
• A review of recent advances in anti-tubercular drug development.

  2020cites this paper
• Modulation of the M. tuberculosis cell envelope between replicating and non-replicating persistent bacteria.

  2020cites this paper
• An overview of new antitubercular drugs, drug candidates, and their targets

  2020cites this paper